LumiThera
Poulsbo, Washington, United States · Healthcare, Health Care, Information Technology
LumiThera, Inc. is a commercial-stage medical device company initially focused on treating patients affected by dry age-related macular degeneration. The Company’s expertise is in the application of photobiomodulation (“PBM”), using non-invasive light emitting diodes (“LED”) for acute and chronic ocular diseases and disorders. The Company is developing an ophthalmic LED office-based instrument to
Key facts
- Headquarters
- Poulsbo, Washington, United States
- Employees
- 37
- Industries
- Healthcare, Health Care, Information Technology
- Status
- Private
- Website
- lumithera.com
- Company page
Recent activity at LumiThera
- : LumiThera
- : LumiThera Inc. announces FDA authorization of Valeda Light Delivery System to improve vision in dry AMD patients.
- : LumiThera
- : LumiThera, Inc
- : Lumithera, Inc. Announces Purchase Of Maculogix Assets
- : Lumithera, Inc. Announces Completion Of Diopsys, Inc. Acquisition
- : LumiThera, Inc.
- : LumiThera, Inc.
- : LumiThera, Inc.
- : LumiThera, Inc.
LumiThera funding history
| Date | Round | Amount |
|---|---|---|
| May 2024 | Seed | $2.4M |
| Sep 2022 | Seed | $10.0M |
| Dec 2020 | Seed | $615K |
| Jul 2019 | Seed | $1.0M |
| Mar 2019 | Seed | $100K |
Leadership
- Clark Tedford, Executive Officer, Director
- Daniel Bertholet, Director
- Yang Yigang, Director
- Clark E. Tedford, Executive Officer, Director
- YIGANG YANG, Director
- ARTHUR TAYLOR, Director
- Art Taylor, Director
Verified email and direct lines for LumiThera’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
LumiThera files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Mar 2027.
LumiThera in the news
- LumiThera announces top-line results from LIGHTSITE IIIB extension trial assessing the Valeda Light Delivery System - Optometry Times (May 13, 2025)
- Photobiomodulation For Dry AMD: Ready For Its Day in The Sun? - Ophthalmology Advisor (Mar 20, 2024)
- Alcon to acquire LumiThera and its photobiomodulation device for the treatment of dry AMD - Ophthalmology Times (Jul 07, 2025)
- FDA Authorizes Light Therapy for Dry AMD - American Academy of Ophthalmology (Jan 21, 2025)
- Alcon to buy LumiThera’s light-based therapy for dry AMD - Fierce Biotech (Jul 08, 2025)
- Eye care giant Alcon acquires LumiThera, a Seattle-area startup behind device that treats vision loss - GeekWire (Sep 15, 2025)
- Swiss eye-care giant acquires Poulsbo medical device firm - The Business Journals (Sep 15, 2025)
- Alcon to Acquire LumiThera, Maker of Photobiomodulation Device for the Treatment of Dry AMD - Eyewire+ (Jul 07, 2025)
Companies similar to LumiThera
- Solana Company · Healthcare, Health Care, Information Technology
- Covera Health · Healthcare, Health Care, Information Technology
- Embr Labs, Inc · Healthcare, Health Care, Information Technology
- EnsoData · Healthcare, Health Care, Information Technology
- Ambient Clinical Analytics · Healthcare, Health Care, Information Technology
About LumiThera: questions and answers
What does LumiThera do?
LumiThera, Inc. is a commercial-stage medical device company initially focused on treating patients affected by dry age-related macular degeneration. The Company’s expertise is in the application of photobiomodulation (“PBM”), using non-invasive light emitting diodes (“LED”) for acute and chronic ocular diseases and disorders. The Company is developing an ophthalmic LED office-based instrument to
Where is LumiThera headquartered?
LumiThera is headquartered in Poulsbo, Washington, United States.
How many employees does LumiThera have?
LumiThera has about 37 employees.
Has LumiThera raised funding?
Yes. Fundz has recorded 5 funding events for LumiThera. The most recent, Seed of $2.4M, was in May 2024.
What is the latest news on LumiThera?
On Feb 26, 2025, LumiThera
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy